Inositol for Blood Sugar

Inositol is the entry on this page with the most specific indication. It is not a general blood-sugar supplement; it is a targeted one, and the target is polycystic ovary syndrome, where insulin resistance drives the reproductive and androgen problems rather than the other way round.

Evidence tier 1 in PCOS specifically. Outside that population the case is much weaker.

Table of Contents

  1. Vitamin B8
  2. A Second Messenger, Not an Antioxidant
  3. What the PCOS Evidence Shows
  4. Gestational Diabetes
  5. Hypothyroidism and Hashimoto's
  6. Dosing
  7. Cautions
  8. Key Research Papers
  9. Connections
  10. Featured Videos

Vitamin B8

Inositol is the compound that carried the designation vitamin B8. This is worth stating plainly because it is routinely mixed up with choline, which is sold alongside it in almost every combination product:

Neither is a vitamin under the modern definition, and that is exactly why both lost their numbers: a vitamin is something the body cannot make, and the body makes both. Inositol is synthesised from glucose — roughly a gram a day — which is a detail worth holding onto, because it means supplemental inositol is topping up a pool the body already fills, not replacing something absent. Former vitamins has the full cross-reference of retired designations.

Back to Table of Contents

A Second Messenger, Not an Antioxidant

Most entries on this page are antioxidants or enzyme cofactors. Inositol is neither. Myo- and D-chiro-inositol are precursors of inositol phosphoglycans, which act as second messengers inside the insulin signalling cascade itself — the relay between the insulin receptor at the cell surface and the machinery that moves glucose transporters into the membrane.

That is a more direct mechanism than anything else here, and it explains the tissue specificity. In PCOS the defect is partly a signalling defect in ovarian and muscle tissue, so supplying more of the messenger is a coherent intervention rather than a general metabolic tonic.

Products commonly combine myo- and D-chiro-inositol in a 40:1 ratio, chosen to mirror the physiological ratio in plasma. The evidence that this specific ratio outperforms myo-inositol alone is weaker than the marketing implies.

Back to Table of Contents

What the PCOS Evidence Shows

Tienforti and colleagues' 2026 systematic review in Clinical Endocrinology found inositol supplementation significantly reduced total testosterone (SMD −1.30; 95% CI −2.17 to −0.42), calculated free testosterone and the free androgen index, while raising sex hormone-binding globulin. Substantial heterogeneity was present for several outcomes.

The more useful part of that paper is its title: metabolic phenotype predicts the response. The largest effects were not spread evenly — they concentrated in particular subgroups. That is the same lesson as magnesium in a different guise: who you are changes what the supplement does, and a pooled average across mixed populations understates the effect in the people it fits.

For context on where inositol sits against pharmaceuticals, Omarion and colleagues' 2026 network comparison in Frontiers in Endocrinology put GLP-1 receptor agonists, metformin and inositol side by side across sixteen RCTs. GLP-1 plus metformin was the most effective for weight and BMI. Inositol is the gentlest option in that comparison, not the strongest.

Back to Table of Contents

Gestational Diabetes

This is arguably inositol's strongest indication, and it is stronger than the PCOS case that gets more attention.

Poyatos-León and colleagues' 2026 systematic review and meta-analysis in the American Journal of Obstetrics and Gynecology pooled 12 randomised controlled trials comprising 4,765 women and found myo-inositol supplementation substantially reduced the risk of gestational diabetes compared with control, with most trials of moderate to high quality.

Shi and colleagues' 2026 network meta-analysis in Healthcare put that result in competitive context. Across 59 trials and 10,262 women evaluating 24 different nutritional strategies for preventing and managing gestational diabetes, inositol was associated with a reduced incidence of the condition among high-risk pregnant women (RR 0.50; 95% CI 0.37 to 0.68) and lower fasting glucose (SMD −0.42), ranking highly among all strategies compared.

A halving of risk, replicated across two independent 2026 analyses of overlapping but large literatures, is a stronger signal than anything else on this page produces. The population is specific — women at elevated risk of gestational diabetes — and inositol in pregnancy is a decision for the person managing the pregnancy, not a self-directed one.

Back to Table of Contents

Hypothyroidism and Hashimoto's

Inositol has a second, quite separate application that has nothing to do with glucose, and it is included here because the two conditions overlap heavily in the same patients: subclinical hypothyroidism from Hashimoto's thyroiditis.

The intervention studied is myo-inositol combined with selenium, not inositol alone. The rationale is mechanistic: inositol participates in the TSH receptor's second messenger cascade in thyroid follicular cells, while selenium is required by the glutathione peroxidases and deiodinases that protect the thyroid from the peroxide it generates making hormone.

Nordio and Basciani's 2017 trial in the European Review for Medical and Pharmacological Sciences reported that after six months of combined myo-inositol and selenium, TSH, anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) antibodies all fell significantly, with a significant rise in free T4 — a restoration of the euthyroid state. Stanchev and colleagues' 2026 systematic review and meta-analysis in the Journal of Clinical Medicine compared myo-inositol plus selenium against selenium alone in exactly this population, which is the comparison that isolates what the inositol contributes.

Two things to keep in proportion. The endpoints are biochemical — TSH and antibody titres — rather than long-term outcomes such as progression to overt hypothyroidism, and subclinical hypothyroidism is a condition whose treatment thresholds are genuinely debated. This is a reasonable adjunct to discuss with whoever manages your thyroid, not a replacement for levothyroxine where that is indicated.

The connection back to this section is real rather than incidental: hypothyroidism worsens insulin resistance, raises lipids and slows metabolic rate, so a thyroid left undertreated makes every other intervention on the blood sugar hub work harder.

Back to Table of Contents

Dosing

The common regimen is 2 g of myo-inositol twice daily — 4 g a day — often with 50 mg of D-chiro-inositol to give the 40:1 ratio. It is a powder with a faintly sweet taste and dissolves in water.

Effects on cycle regularity and ovulation in PCOS are typically reported over three to six months, not weeks. Inositol is well tolerated; gastrointestinal upset at higher doses is the usual complaint.

Back to Table of Contents

Cautions

  1. It lowers blood glucose, and so does your medication. The effects add. With insulin or a sulfonylurea this is a hypoglycemia risk, and dose changes belong with the prescriber — see hypoglycemia awareness and prevention.
  2. PCOS needs a diagnosis. Irregular cycles have several causes, and treating presumed PCOS with a supplement is not a substitute for finding out.
  3. If you are trying to conceive, inositol affects ovulation — which is often the point, but it means it should be part of a plan rather than an unmentioned addition to one.
  4. Measure, do not assume. Adding a supplement without measuring means you learn about an interaction from a symptom rather than from a number.

Back to Table of Contents

Key Research Papers

Every DOI below was checked against Crossref and the abstract read for support before it was listed.

  1. Tienforti, et al. Metabolic Phenotype Predicts Biochemical Response to Inositol Supplementation in Polycystic Ovary Syndrome: A Systematic Review. Clinical Endocrinology, 2026;105(2):237–244.
  2. Omarion, et al. Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes. Frontiers in Endocrinology, 2026;17:1833904.
  3. Poyatos-León R, et al. The effect of myo-inositol supplementation on gestational diabetes mellitus prevention: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2026. Twelve RCTs, 4,765 women.
  4. Shi, et al. Effects of Different Nutritional Strategies on the Prevention and Management of Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. Healthcare, 2026;14(16):2593. Fifty-nine trials, 10,262 women; inositol RR 0.50 for GDM incidence.
  5. Stanchev, et al. Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto's Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2026;15(9):3179.
  6. Nordio M, Basciani S. Myo-inositol plus selenium supplementation restores euthyroid state in Hashimoto's patients with subclinical hypothyroidism. European Review for Medical and Pharmacological Sciences, 2017;21(2 Suppl):51–59. PubMed record — no DOI assigned.

Live PubMed Topic Searches

  1. Inositol and PCOS
  2. The 40:1 ratio
  3. Inositol second messengers
  4. Inositol and gestational diabetes
  5. Inositol, selenium and Hashimoto's

Back to Table of Contents

Connections

Back to Table of Contents